{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:07:50Z","timestamp":1787508470061,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of cholangiocarcinoma (CCA) continues to face numerous clinical challenges, including the prediction of sensitivity to immunotherapy and the development of preoperative diagnostic models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we aimed to address these challenges by collecting bile samples from CCA patients for metabolomic and microbiomic analyses. We also performed immunofluorescence (IF) staining on tissue formalin-fixed, paraffin-embedded (FFPE) blocks to assess the expression of relevant biomarkers. Additionally, we followed up with patients to analyze prognostic indicators based on their survival times. Using advanced machine learning techniques, specifically LASSO regression, we constructed a predictive model to determine the effectiveness of programmed cell death protein 1 (PD-1) inhibitors in treating CCA. The model integrates bile metabolomic data with an Immune Hot-Cold Index (IHC Index) derived from IF results, providing a comprehensive metric of the patient\u2019s immune environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings revealed significant differences in metabolomic profiles between CCA patients and those with non-malignant liver diseases, as well as between patients with different genetic mutations. The IHC Index successfully differentiated between immune \u201chot\u201d and \u201ccold\u201d states, correlating strongly with patient responses to immunotherapy. Furthermore, in one CCA patient, the model\u2019s predictions were validated, demonstrating high accuracy and clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our predictive model offers a robust tool for assessing the sensitivity of CCA patients to PD-1 inhibitors, potentially guiding personalized treatment strategies. Additionally, the integration of bile metabolomics with IF data provides a promising approach for developing preoperative diagnostic models, enhancing early detection and treatment planning for CCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1614683","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T02:09:15Z","timestamp":1750039755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Machine learning-driven prediction of immune checkpoint inhibitor responses against cholangiocarcinoma: a bile biopsy perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Dengyong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"Xu","year":"2018","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0269","article-title":"TOPAZ-1: a new standard of care for advanced biliary tract cancers","volume":"15","author":"Ebia","year":"2023","journal-title":"Immunotherapy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2011.00296.x","article-title":"Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma","volume":"13","author":"Hashim Abdalla","year":"2011","journal-title":"HPB"},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1477-2574.2010.00185.x","article-title":"Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy","volume":"12","author":"Sharif","year":"2010","journal-title":"HPB"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/02841850802220092","article-title":"Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis","volume":"49","author":"Albiin","year":"2008","journal-title":"Acta Radiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/febs.2013.280.issue-12","article-title":"Oxidized phosphatidylcholines in membrane-level cellular signaling: from biophysics to physiology and molecular pathology","volume":"280","author":"Volinsky","year":"2013","journal-title":"FEBS J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.1038\/s41598-018-29445-z","article-title":"Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma","volume":"8","author":"Song","year":"2018","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/metabo10070282","article-title":"Development and validation of a highly sensitive LC-MS\/MS method for the analysis of bile acids in serum, plasma, and liver tissue samples","volume":"10","author":"Gomez","year":"2020","journal-title":"Metabolites"},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-023-00507-3","article-title":"Cancer metabolites: promising biomarkers for cancer liquid biopsy","volume":"11","author":"Wang","year":"2023","journal-title":"biomark Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1038\/s41598-023-27603-6","article-title":"Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1123","article-title":"Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma","volume":"78","author":"Hill","year":"2018","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000518104","article-title":"Immune checkpoint inhibitors: the emerging cornerstone in cholangiocarcinoma therapy","volume":"10","author":"Gutierrez-Larranaga","year":"2021","journal-title":"Liver Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1614683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T02:09:16Z","timestamp":1750039756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1614683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1614683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1614683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"article-number":"1614683"}}